Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.75 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807670 | 0.97 | BACE1 (0.73) | BACE1CNR1CNR2DRD2DRD4 | |
| SCHEMBL4807276 | 0.90 | BACE1 (0.72) | BACE1CNR1HPGD | |
| SCHEMBL4812366 | 0.89 | BACE1 (0.73) | BACE1 | |
| SCHEMBL4805139 | 0.88 | BACE1 (0.73) | BACE1 | |
| SCHEMBL4812107 | 0.86 | BACE1 (0.71) | BACE1 | |
| SCHEMBL4815325 | 0.82 | BACE1 (0.73) | BACE1HPGD | |
| SCHEMBL4808649 | 0.78 | BACE1 (0.73) | BACE1 | |
| SCHEMBL5803571 | 0.70 | BACE1 (0.73) | BACE1 | |
| SCHEMBL5804999 | 0.70 | BACE1 (0.59) | BACE1 | |
| SCHEMBL4810047 | 0.69 | BACE1 (0.62) | BACE1CNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459567-B2 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2008-12-02 | — | — | US | claimed |
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2006-08-17 | — | — | US | claimed |
| US-7459567-B2 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | BACE1, BACE2, PSEN1 | BACE1 1/4885CNR1 2016/4885CNR2 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.